MethylGene Oncology Agent Shows Activity In NHL Clinical Trial
MGCD0103 shows 15 percent response rate in subset of NHL patients, tumor shrinkage, firm reports at ASCO.
MGCD0103 shows 15 percent response rate in subset of NHL patients, tumor shrinkage, firm reports at ASCO.